hollow vaccines

Popular Science highlights this paper from PLOS Pathogens. The research discusses creating hollowed out versions of viral capsids. These capsids would stimulate the immune system to produce antibodies without any potential for infection since the virus’ genetic material has been removed.

Call it hollow-hearted. Researchers have built a mimic of the outer capsule of the foot-and-mouth disease virus. Inside, where the virus’ genetic material normally lives, is empty.

Such synthetic virus-like particles could go into a foot-and-mouth vaccine that’s cheaper to make because it doesn’t require the tight biosecurity that a factory that makes vaccines from live viruses needs, its creators say. The researchers have also built the virus mimic in such a way that it can stay out of a refrigerator for longer than current foot-and-mouth vaccines, so it could ship more easily around the world.

In the future, the same techniques could apply to vaccines to the polio virus, which belongs to a large group of viruses related to hoof-and-mouth, Andrew Macadam, a polio researcher at the U.K. National Institute for Biological Standards and Control, told the BBC. Polio vaccines are now made with either weakened or killed polio viruses. (The weakened type still carries a small risk of reverting to its original form and causing paralysis. That vaccine is no longer used in the U.S., but some other countries give it out because it doesn’t require a highly trained medical professional to administer.)

The researchers hope it will lead to cheaper and less risky vaccines.

malaria vaccine is a let down

A vaccine for malaria that was in clinical trials turns out not to produce robust effects. In a clinical trial only about 30% of study participants gained immunity as a result of the vaccine. From the NY Times:

Three shots of the vaccine, known as RTS, S or Mosquirix and produced by GlaxoSmithKline, gave babies fewer than 12 weeks old 31 percent protection against detectable malaria and 37 percent protection against severe malaria, according to an announcement by the company at a vaccines conference in Cape Town.

Last year, in a trial in children up to 17 months old, the same vaccine gave 55 percent protection against detectable malaria and 47 percent against severe malaria.

The new trial “is less than we’d hoped for,” Moncef Slaoui, Glaxo’s chairman of research and development said in a telephone interview. “But if a million babies were vaccinated, we would prevent 260,000 cases of malaria a year. This is a disease that kills 655,000 babies a year — 31 percent of that is a very large number.”

The company, which has already spent more than $300 million on the vaccine, wants to keep forging ahead, he said, “but it is not just our decision.”

The research was at least partially funded by the Bill & Melinda Gates Foundation.